
James L M Ferrara MD
Hematologic Oncology
Professor and Director of Hematologic Malignancies Translational Research Center
Join to View Full Profile
10 E 102nd StNew York, NY 10029
Phone+1 212-241-6756
Fax+1 646-537-9576
Dr. Ferrara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Oxford UniversityD.Sc, Medical Sciences, 2009 - 2009
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1985
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1981 - 1982
Boston Children’s Hospital/Boston Medical CenterInternship, Pediatrics, 1980 - 1981
Georgetown UniversityMA, Cum Laude, 1980 - 1980
Certifications & Licensure
NY State Medical License 2015 - 2026
MI State Medical License 1998 - 2015
Awards, Honors, & Recognition
- Ward-Coleman Chair in Cancer Medicine Icahn School of Medicine, 2014
- Nobel Lecture Karolinska Institutet, Stockholm, Sweden, 2012
- Visiting Fellowship All Soul’s College, Oxford, England, 2011
Clinical Trials
- Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Publications & Presentations
PubMed
- Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.Ioannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos
Transplantation and Cellular Therapy. 2026-01-01 - 1 citationsThe MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis E Louloudis, Paibel Aguayo-Hiraldo
Blood Advances. 2025-11-25 - 2 citationsRemestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.Aaron Etra, James L M Ferrara, John E Levine
Blood. 2025-10-16
Journal Articles
- Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused p...Smith BR, Guinan EC, Parkman R, Ferrara JLM, Levey RH, Nathan DG, Rappeport JM, Transplantation
- Cutaneous acute graft-versus- host disease to minor histocompatibility antigens in a murine model: Histologic analysis and correlation to clinic disease.Ferrara JLM, Guillén FJ, Sleckman B, Burakoff SJ, Murphy GF, J Invest Dermatol
- Acute cutaneous graft-versus-host disease to minor histocompatibility antigens in a murine model: Evidence that large granular lymphocytes are effector cells...Guillén FJ, Ferrara JLM, Hancock WW, Messadi D, Fonferko E, Burakoff SJ, Murphy GF, Lab Invest
Books/Book Chapters
Abstracts/Posters
- The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host DiseaseJames L. M. Ferrara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation60th American Society of Hematology Annual Meeting - 12/2/2018
- Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation60th American Society of Hematology Annual Meeting - 12/1/2018
Other
- Lab Focus: James Ferrara.Ferrara JLM, BSBMT News
http://www.bsbmt.org/pages/232-Newsletter_7_April_10 - Michigan in the News.Ferrara J
http://www.ur.umich.edu/update/archives/100107
The University Record. Retrieved - New test could discern serious condition early after bone marrow transplant.Ferrara JLM, Science News
Press Mentions
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding From National Cancer InstituteOctober 22nd, 2025
Could a Vaccine Passport Soon Be Your Ticket to a Quarantine-Free Vacation?May 4th, 2021
Novartis, Juno Face Production Hurdles for New Blood Cancer DrugsJanuary 13th, 2016
Grant Support
- TCI Mentored Medical Student Summer Scholars (TCI-MMSSS) ProgramICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2023–2028
- The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical OncologyICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2022–2027
- Cellular and Molecular Studies of Bone Marrow TransplantICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1997–2027
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









